Evidence map›Paper›PMID 42052775›Full record

ReviewThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2026

Paraoxonase 2 as a target for aging-related diseases.

Hyeong Hwan Kim, Ye Jin Kang, Jae Ho Lee, Hyeong Min Lee, Hyung Soon Park, Chang-Hoon Nam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hyeong Hwan KimAging and Immunity Laboratory, Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Korea.
Ye Jin KangAging and Immunity Laboratory, Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Korea.
Jae Ho LeeGlaceum Incorporation, Research Department, Suwon 16675, Korea.
Hyeong Min LeeGlaceum Incorporation, Research Department, Suwon 16675, Korea.
Hyung Soon ParkGlaceum Incorporation, Research Department, Suwon 16675, Korea.
Chang-Hoon NamAging and Immunity Laboratory, Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu 42988, Korea.ORCID https://orcid.org/0000-0002-3570-7802

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraoxonase 2 (PON2) is an enzyme exhibiting both lactonase and esterase activities, widely distributed across various tissues and localized within cellular mitochondria. It plays a vital role in innate immunity by restricting bacterial infections and has diverse functions, including the regulation of mitochondrial reactive oxygen species levels and the management of endoplasmic reticulum stress. By alleviating oxidative stress, stabilizing mitochondria, and modulating apoptosis, PON2 emerges as a significant factor in the study of cellular senescence. This review consolidates recent findings regarding PON2's physiological roles, its mechanistic connections to senescence, and the therapeutic potential of modulating its activity. Our analysis highlights PON2's considerable promise as a target for aging-related diseases, including neurodegeneration, metabolic disorders, cardiovascular diseases, chronic inflammation, and cancer.

Indexed as

Cellular senescenceInflammationMetabolic diseaseOxidation-ReductionParaoxonase-2

Identifiers

PMID42052775
PMCPMC13321990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.